AUTOLUS THERAPEUTICS PLC (AUTL) Stock News

USA - NASDAQ:AUTL - US05280R1005 - ADR

1.54 USD

-0.11 (-6.67%)

Last: 10/28/2025, 4:30:01 PM

1.56 USD

+0.02 (+1.3%)

After Hours: 10/28/2025, 4:30:01 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

AUTL Latest News, Press Relases and Analysis

All

Press Releases

a day ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

a day ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the American College of Rheumatology Convergence 2025

8 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

8 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces First Patient Dosed in Phase 1 Trial of Obecabtagene Autoleucel (Obe-Cel) in Patients with Progressive Multiple Sclerosis

5 months ago - By: Benzinga

What 4 Analyst Ratings Have To Say About Autolus Therapeutics

6 months ago - By: Benzinga - Mentions: MSC ELUT ACIW JYNT ...

Earnings Scheduled For May 8, 2025

13 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

13 days ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

a month ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

a month ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Present Clinical Data Update at the American College of Rheumatology (ACR) Convergence 2025

3 months ago - By: Yahoo Finance

Autolus Therapeutics sees cash runway to launch, commercialization of obe-cel

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates

3 months ago - By: Yahoo Finance - Mentions: ELTX

Unlocking Oncology’s Future: 3 Trending Cancer Biotech Stocks with ‘Strong Buy’ Ratings

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Report Second Quarter 2025 Financial Results and Host Conference Call on August 12, 2025

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

3 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics’ CAR T Therapy AUCATZYL® (Obecabtagene Autoleucel) Granted European Marketing Authorization for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

4 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Long-Term Follow Up from the FELIX Study Demonstrating Obe-Cel's Potential for Long-Term Remission in R/R B-ALL at the 2025 European Hematology Association (EHA) Congress

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics to Participate in Upcoming Investor Conferences

5 months ago - By: Stocktwits - Mentions: SBIO KOMP

Autolus Therapeutics Gets Favorable Recommendation For Approval Of Cancer Therapy In EU: Retail Sentiment Brightens

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

5 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces Positive CHMP Opinion for Obecabtagene Autoleucel for Adult Patients (age 26 and older) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)

5 months ago - By: Yahoo Finance - Mentions: DHI CMG

Autolus Therapeutics plc (AUTL): Analysts See 697% Upside Potential

6 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

6 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Presents Clinical Data Updates at the 2025 European Hematology Association (EHA) Congress

6 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Reports First Quarter 2025 Financial Results and Business Updates

6 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

6 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Announces License of AUCATZYL® (obecabtagene autoleucel) Issued by UK MHRA for Adult Patients (≥ 18 years) with Relapsed or Refractory B-Cell Precursor Acute Lymphoblastic Leukemia (R/R B-ALL)(1)

6 months ago - By: Autolus Therapeutics plc

Autolus Therapeutics Highlights Advancing Autoimmune Pipeline at R&D Investor Event